| 西格列汀与格列齐特缓释片联用甘精胰岛素治疗2型糖尿病的疗效与安全性评价 |
| |
| 引用本文： | 张丹丹,李会英,毛玉山,吴伦,黄静. 西格列汀与格列齐特缓释片联用甘精胰岛素治疗2型糖尿病的疗效与安全性评价[J]. 中国临床保健杂志, 2017, 20(1): 67-70 |
| |
| 作者姓名： | 张丹丹 李会英 毛玉山 吴伦 黄静 |
| |
| 作者单位： | ;1.宁波大学医学院附属医院药剂科;2.宁波大学医学院附属医院内分泌科 |
| |
| 基金项目： | 宁波大学校级科研项目(XYY16048) |
| |
| 摘 要： | 目的 对西格列汀与格列齐特缓释片联合甘精胰岛素治疗2型糖尿病(T2DM)的疗效和安全性进行比较。方法 以83例T2DM患者为研究对象,按照随机数字表法分为观察组与对照组。观察组使用西格列汀联合甘精胰岛素的用药方案,对照组使用格列齐特缓释片联合甘精胰岛素的用药方案。均治疗16周,监测治疗前后空腹血糖(FPG)、餐后2 h血糖(2h PG)、糖化血红蛋白(Hb A1c)、空腹胰岛素水平(FIns)、胰岛素抵抗指数(HOMA-IR)、体质量指数(BMI)等指标以及胰岛素用量、不良反应的发生情况。结果 治疗后两组的血糖控制均改善,FPG、2h PG、Hb A1c、HOMA-IR水平较治疗前均明显下降,FIns均明显升高(P0.05)。治疗后水平比较,对照组FPG降低较观察组明显(P0.05),但是观察组2h PG降低更明显(P0.05);Hb A1c达标率、HOMA-IR两组间前后差值比较,差异无统计学意义(P0.05)。观察组的BMI水平较对照组下降了6.25%,胰岛素用量减少了12.92%,差异有统计学意义(P0.05)。安全性方面,观察组低血糖的发生率(2.38%),与对照组(9.76%)比较,差异有统计学意义(P0.05)。结论 西格列汀联用甘精胰岛素治疗2型糖尿病使血糖控制良好,安全性高。
|
| 关 键 词： | 糖尿病,2型 格列齐特 二肽基肽酶Ⅳ抑制剂 |
| 收稿时间： | 2016-09-19 |
Comparison of the efficacy and safety of the sitagliptin plus glargine insulin or the gliclazide plus glargine insulin in patients with type 2 diabetes |
| |
| Zhang Dandan,Li Huiying,Mao Yushan,Wu Lun and Huang Jing. Comparison of the efficacy and safety of the sitagliptin plus glargine insulin or the gliclazide plus glargine insulin in patients with type 2 diabetes[J]. Chinese Journal of Clinical Healthcare, 2017, 20(1): 67-70 |
| |
| Authors: | Zhang Dandan Li Huiying Mao Yushan Wu Lun Huang Jing |
| |
| Affiliation: | Department of Pharmacy,the Affiliated Hospital of Ningbo University,Ningbo 315020,China,Department of Pharmacy,the Affiliated Hospital of Ningbo University,Ningbo 315020,China,Department of Pharmacy,the Affiliated Hospital of Ningbo University,Ningbo 315020,China,Department of Pharmacy,the Affiliated Hospital of Ningbo University,Ningbo 315020,China and Department of Pharmacy,the Affiliated Hospital of Ningbo University,Ningbo 315020,China |
| |
| Abstract: | Objective To investigate the efficacy and safety of the sitagliptin plus glargine insulin or the gliclazide plus glargine insulin in patients with type 2 diabetes.Methods Eighty-three patients with type 2 diabetes were randomly assigned to 2 group.The observation group was treated with sitagliptin plus glargine insulin,and control group was treated with gliclazide plus glargine insulin.The duration of treatment was 16 weeks.FPG,2hPG,HbA1c,FIns,HOMA-IR,BMI,insulin dosage and adverse events were recorded.Results Glycemic control was improved in both groups.FPG,2hPG,HbA1c,HOMA-IR were significantly decreased compared to pretreatment,FIns were significantly increased(P<0.05),FPG in control group were lower than those in observation group(P<0.05),but 2hPG in observation group were lower than those in control group(P<0.05);HbA1c targeting rate,HOMA-IR between the two groups had no significant difference.But the BMI level in observation group down by 6.25% compared with control group,also the insulin dose was reduced by 12.92%,the difference was statistically significant.There was significant difference between observation group(2.38%)and control group(9.76%) in the proportion of hypoglycemia too.Conclusion Sitagliptin combined with glargine had better effect safety in the treatment of type 2 diabetes. |
| |
| Keywords: | |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《中国临床保健杂志》浏览原始摘要信息 |
|
点击此处可从《中国临床保健杂志》下载免费的PDF全文 |
|
